GLOW is a 70 mg vial of 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 sold for skin and tissue repair.
A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.
Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.
Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.
Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.
Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.
The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.
GLOW is 3 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.
GHK-Cu50 mg per vial
BPC-15710 mg per vial
TB-500 / TB-410 mg per vial
What published studies and recent community write-ups report about amounts, timing and course length. 1 preclinical and 5 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical1 row | |||||
| Related two-peptide combination in rats: BPC-157 plus TB-500 after Achilles tendon repair (not the GLOW product)32 male Sprague-Dawley rats, 8 per group, after Achilles tendon transection and repair | BPC-157 10 mcg/kg per day; TB-500 60 mcg/kg per day; both together in the combination group | Once daily | Intraperitoneal | 4 weeks after surgeryNot applicable | Joint Diseases and Related Surgery (PubMed)2026 |
| TB-500 alone raised maximum load to failure significantly and improved tendon histology; BPC-157 alone improved scores without reaching significance; and the combination improved one histology score but added nothing over either agent on its own, which the authors attribute to shared downstream pathways. There was no GHK-Cu arm and no human data, so this is the closest published test of GLOW's synergy claim and it does not support it. | |||||
| Community-reported5 rows | |||||
| Community dosing chart: 70 mg vial in 3 mL, one fixed daily draw for 4 weeks | 2,330 mcg of blend per draw (about 1.67 mg GHK-Cu, 333 mcg BPC-157 and 333 mcg TB-500), measured as 10 units (0.10 mL) at 23.3 mg/mL | Once daily | Subcutaneous, U-100 insulin syringe | 4 weeks2-4 weeks off before any repeat | Community resource2025 |
| This chart reconstitutes the 70 mg vial with 3 mL of bacteriostatic water so that one unit holds about 233 mcg of blend and the vial gives roughly 30 draws. It also works the 2 mg GHK-Cu question: a 12-unit (0.12 mL) draw lands GHK-Cu at 2 mg and necessarily carries 400 mcg each of BPC-157 and TB-500, because the ratio cannot be changed. The page says the schedule and the 5:1:1 split come from product materials rather than any approved dosing, notes that BPC-157 and TB-500 are WADA-prohibited, and ends with a vendor recommendation, so it is a commercial protocol page. | |||||
| Community schedule: fixed 10-unit draw with a frequency taper over 8-12 weeks | 10 units (0.10 mL), about 2.33 mg of blend, from 70 mg reconstituted in 3 mL | Daily in weeks 1-4, five times a week in weeks 5-8, then 2-3 times a week | Subcutaneous | 8-12 weeks on4-8 weeks off before another cycle | Community resource2026 |
| The same site's longer guide keeps the draw constant and changes only how often it is given: 7, then 5, then 2-3 injections a week. At those frequencies one 30-draw vial lasts about 4.3 weeks in loading and 10-15 weeks in maintenance. The guide states that there is no registered clinical trial of the GLOW blend, calls the combination-level evidence a genuine gap, and frames the choice between GLOW and KLOW as a question of whether reactive skin wants the KPV component, which is a marketing heuristic rather than a tested claim. | |||||
| Community calculator and 12-week protocol: 2.5 mL reconstitution | 2.8 mg of blend per injection (2 mg GHK-Cu, 400 mcg BPC-157, 400 mcg TB-4) as 10 units at 28 mg/mL; the page's stated range is 1.4-4.2 mg per injection | Daily in weeks 1-4 (activation), five times a week in weeks 5-8 (remodeling), 2-3 times a week in weeks 9-12 (maintenance) | Subcutaneous | 12 weeks4-8 weeks off | Community resource2026 |
| One community calculator picks 2.5 mL of bacteriostatic water so that a 2 mg GHK-Cu target falls on exactly 10 units, and counts 56-60 injections per course against 25 doses per vial by mass. Because it applies the 28-day multi-dose vial convention, it concludes that three vials are needed for one 12-week run. The page asserts that GLOW vials contain full-length thymosin beta-4 rather than the 7-residue TB-500 fragment and says labels blur the two; which form a given vial holds is a question for that vendor's lab report, and the PubChem card on this site's TB-500 page is the fragment. It also computes about 316 mcg of elemental copper per 2 mg GHK-Cu dose and notes that no published report has measured copper status in anyone injecting GHK-Cu. | |||||
| Community reconstitution guide: water volume, what 10 units delivers, and what forum users draw | 10-12 units on a 3 mL mix (2.33-2.8 mg of blend) as the most-described draw, with 5-6 units for the first few days | Not fixed by the guide; it plans the vial as 20-30 draws | Subcutaneous, fresh insulin syringe for every draw | 28 days per reconstituted vial by multi-dose conventionNot described | Community resource2026 |
| The guide's table gives 35, 28 and 23.3 mg/mL for 2, 2.5 and 3 mL of bacteriostatic water, so 10 units delivers 3.5, 2.8 or 2.33 mg of blend with GHK-Cu making up five sevenths of each. It quotes Pickart's 2015 finding that GHK-Cu was stable in water at pH 4.5-7.4 for two weeks at 60 degrees and places bacteriostatic water at about pH 5.7, inside that window, and it expects a clear blue to blue-green solution. It collects forum experience: vials used for 10-16 weeks with no visible change but unmeasured potency, one buyer whose vial turned out to be 70/12.5/11 mg rather than 50/10/10, and injection-site pain that users attribute to the copper peptide and manage with more water, a slower push and a longer needle. | |||||
| Community reconstitution chart: 2 mL for round-number draws | 3.5 mg of blend per 10 units (2.5 mg GHK-Cu, 500 mcg BPC-157, 500 mcg TB-500) at 35 mg/mL from 70 mg in 2 mL; 5 and 15 unit rows are also tabulated | Five times a week in a loading phase, three times a week in maintenance | Subcutaneous, 29-31 gauge insulin syringe | One vial lasts about 4 weeks at five draws a week or about 6.5 weeks at threeNot described | Community resource2026 |
| This guide prefers 2 mL because 10 units then equals exactly 3.5 mg and, in its reading, puts each component inside its standalone community range (1-2 mg GHK-Cu, 250-500 mcg BPC-157, 250-750 mcg TB-500). It gives 28 days refrigerated for a vial made with bacteriostatic water and 24 hours with plain sterile water, treats a faint blue-green tint as expected copper chemistry, and warns people who keep both blends not to draw from a KLOW (80 mg) vial using GLOW (70 mg) arithmetic. | |||||
The 70 mg vial is made up with 2-3 mL of bacteriostatic water released down the glass wall and swirled, never shaken. 3 mL gives 23.3 mg/mL and about 30 draws of 10 units, 2.5 mL puts a 2 mg GHK-Cu draw on 10 units, and 2 mL gives round numbers at 35 mg/mL. The solution should be clear and faintly blue from the copper.
Every guide found starts with one draw a day. The charts use 10 units (2.33 mg of blend at 3 mL, or 2.8 mg at 2.5 mL) and keep that size constant for the whole course; one vial covers roughly this phase.
The frequency drops to five injections a week with the same draw. One chart instead stops after week 4 and takes 2-4 weeks off before repeating, so the two schedules diverge here.
Two to three injections a week, then a 4-8 week break. One community calculator counts 56-60 injections and three vials for the full run because each opened vial is dated at 28 days.
No trial has followed anyone on GLOW, so this timeline is the schedule guides publish, not an observed course. In the one animal study that gave BPC-157 and TB-500 together, four weeks of daily injections improved tendon histology but no more than either peptide alone.
Plus 9 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
What sources report for each peptide on its own. In GLOW the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.
These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.
GLOW is a 70 mg vial of 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 sold for skin and tissue repair. The name is a vendor and community label rather than a research term: the vendor and other research-chemical sellers list it at this 5:1:1 ratio, and guides describe it as the KLOW stack without KPV, marketed for skin quality, collagen and soft-tissue recovery. No study has tested this combination in cells, animals or people, a 2026 rat study that gave BPC-157 and TB-500 together found no added benefit over either peptide alone, and every protocol below is a vendor or community account built around the 70 mg vial.
Fixed-ratio blend reference
Kept separate from single-peptide evidence and terminology.
Structured review queued
No evidence level is assigned until references and study models are reviewed.
Advanced Blend workspace
Calculator access performs arithmetic; it does not establish an amount or protocol.
No reviewed observation on file
The vial label remains the authoritative source for any calculation.
Each number is the vial amount for that component. It is not a per-draw amount.
4 curated references, each with its journal, year and study model, plus 9 community resources reported but not linked.